期刊文献+

齐拉西酮治疗儿童青少年精神分裂症的临床对照研究 被引量:17

Comparative clinical trial of ziprasidone in the treatment of child and adolescent schizophrenia
原文传递
导出
摘要 目的观察齐拉西酮与利培酮对儿童青少年首发精神分裂症的临床疗效与安全性。方法 53例患者随机分为2组,分别用齐拉西酮(26例)或利培酮(27例)治疗,疗程均为8周。以临床疗效总评量表(CGI)、简明精神病评定量表(BPRS)评估有效性;用副反应量表(TESS)和血压、体重等评估安全性和耐受性。结果治疗8周后,BPRS评分,2组均明显低于治疗前,2组间BPRS减分率差异无统计学意义(P>0.05)。齐拉西酮组,未发现月经紊乱及体重增加;利培酮组,发现6例月经紊乱,4例体重增加。锥体外系不良反应,齐拉西酮组明显少于利培酮组(均P<0.05)。结论齐拉西酮治疗儿童青少年精神分裂症疗效确切,与利培酮相当;但不良反应较利培酮少。 Objective To compare the efficacy and safety of ziprasidone and risperidone in the treatment of first onset schizophrenia.Methods Fifty inpatients aged 10-18 diagnosed with schizophrenia using ICD-10 criteria were treated with ziprasidone(26 patients) and risperidone(27 patients) for 8 weeks.Efficacy was assessed by using the clinical global impression(CGI) and the brief psychiatry rating scale(BPRS).The safety and tolerability were assessed by using the treatment emergent symptom scale(TESS).Important physiological parameters including blood pressure and weight were recorded.Results BPRS scores were significantly decreased in both groups after 8-week treatment,but there were no significant difference between two groups(P〉0.05).However,the extrapyramidal reaction of ziprasidone was fewer than that of risperidone(P〈0.05).Paramenia and weight gain was not found in patients treated with ziprasidone,but 6 patients with paramenia(P〈0.05)and 4 patients with weight gain(P〈0.05) were found among patients treated with risperidone.Conclusion Efficacy of ziprasidone is as same as that of risperidone for first onset child and adolescent schizophrenia,but extrapyramidal reaction,paramenia and weight gain are fewer.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2012年第7期493-495,共3页 The Chinese Journal of Clinical Pharmacology
关键词 齐拉西酮 利培酮 精神分裂症 ziprasidone; risperidone; schizophrenia
  • 相关文献

参考文献5

  • 1Kjelby E, JOrgensen HA, Kroken RA, et al. Anti -depressive ef- fectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial[ J ]. BMC Psychiatry,2011 ; 11 : 145.
  • 2Stroup TS, Licberman JA, MeEvoy JP, et al. Results of phase 3 of the CATIE schizophrenia trial[ J]. Schizophr Res ,2009 ; 107 : 1 - 12.
  • 3Lieberman JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials[ J]. J Clin Psychiatry, 2007 ; 68:4.
  • 4张明园.精神科评定量表手册[M].长沙:湖南科学技术出版社,2003.39.
  • 5Zhao T, Park TW, Yang JC. Efficacy and safety of ziprasidone in the treatment of first - episode psychosis: an 8 - week, open - label, multicenter trial [ J ]. lnt Clin Psychopharmacol, 2012 ; [ Epub ahead of print ].

共引文献446

同被引文献117

  • 1翟金国,赵靖平,房茂胜.新型非典型抗精神病药临床应用评价[J].中国新药与临床杂志,2006,25(4):296-301. 被引量:42
  • 2康平,朱海清,胡军.脑梗死后抑郁症药物治疗及其对神经功能康复影响的临床观察[J].中国医药,2007,2(9):543-544. 被引量:6
  • 3余柳霞,蒋庆飞,朱跃华.帕罗西汀合用小剂量齐拉西酮治疗抑郁症的疗效观察[J].现代实用医学,2007,19(8):659-660. 被引量:8
  • 4廖昌莲 潘奎琼 谭小波 等.心理干预对康复期精神分裂症焦虑和抑郁情绪影响的研究.中外健康文摘,2010,7(26):89-89.
  • 5中华医学会精神科分会.中国精神障碍分类与诊断标准[M].3版.济南:山东科学技术出版社,2001:108-1150.
  • 6张豪丽.利培酮及齐拉西酮对首发精神分裂症患者血清脂类的影响研究[J].健康必读(中旬刊),2013,12(1):133-133.
  • 7Birkhofer A, Geissendoerfer J, Alger P, et al. The decelera- tion capacity - a new measure of heart rate variability evaluated in patients with schizophrenia and antipsychotic treatment [ J ]. Eur Psychiatry, 2011, 12 (7) : 65 -68.
  • 8Ray WA, Chung CP, Murray KT, et al. Atypjcal antjpsy- chotic drugs and the risk of sudden cardiac death [J]. N Engl J Med, 2009, 360 (3): 225-235.
  • 9Serretti A, Gibiino S, Drago A. Specificity profile of paroxetine in major depressive disorder: meta-regression of double-blind, ran- domized clinical trials [J]. J Affect Disord, 2011,132 (1-2) : 14-25.
  • 10American Psychiatric Association. Diagnostic and statistical manu- al of mental disorders[ M]. Fourth Edition ( DSM-IV ) . Washing- ton DC: APA,1994:B4-B5.

引证文献17

二级引证文献101

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部